Highlight
– The endTB-Q phase 3 trial evaluated an all-oral regimen combining bedaquiline, delamanid, linezolid, and clofazimine (BDLC) in patients with rifampicin-resistant and fluoroquinolone-resistant tuberculosis.
– The BDLC regimen demonstrated favourable treatment outcomes comparable to the WHO-recommended standard of care but did not establish overall non-inferiority.
– Safety profiles were similar across the BDLC and control groups, with high rates of grade 3 or higher adverse events in both arms.
– Findings suggest that pre-XDR tuberculosis may require prolonged, reinforced treatment regimens beyond shortened ones.